Business
BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors
PALO ALTO, Calif., Aug. 18, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover,
About this update from Bridgebio Pharma, Inc.
[{"type":"text","content":"PALO ALTO, Calif., Aug. 18, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that it has added three new independent directors to its board: Fred Hassan, a pharmaceutical and financial industry giant who is the former CEO of Schering-Plough and former chairman of Bausch & Lomb; Andrea Ellis, a consumer technology innovator and the chief financial officer of Lime; and Douglas Dachille, an investment management veteran and the former chief investment officer of American International Group, Inc. (AIG).\n\n \n \n \n \n \n \n\n \n\"We are privileged to have the opportunity to work with and learn from Fred, Andrea and Doug, and are grateful they are committed to helping us grow and advance our pipeline of potential therapies to treat patients with genetic diseases,\" said BridgeBio founder and CEO Neil Kumar, Ph.D. \"We are confident that the collective guidance these new directors offer will strengthen our ability to serve patients around the world.\"\nFred Hassan\nMr. Hassan brings extensive experience leading and scaling global pharmaceutical companies and advising major corporates as a director, which will benefit BridgeBio as it expands its commercial infrastructure and broadens its reach to patients.\nMr. Hassan works as director at Warburg Pincus LLC, a global private equity institution. Previously, Mr. Hassan was the chairman and chief executive officer of Schering-Plough and chairman and chief executive officer of Pharmacia Corporation, a company formed through the merger of Monsanto Company and Pharmacia & Upjohn, Inc. Mr. Hassan is a director at Prometheus Biosciences, and Precigen, both public biopharma companies using advanced technologies. \nHis previous directorships include Time Warner Inc. until its acquisition by AT&T Inc. in 2018, and Avon Products, where he served as chairman of the board, and Bausch & Lomb, where he also served as chairman. He has also served as a director at Amgen. Mr. Hassan earned a bachelor's degree from Imperial College of Science and Technology, University of London and a master's degree in business administration from Harvard Business School.\n\"BridgeBio is creating something un...